CHRS
Coherus Oncology, Inc.
$1.39
Distressed or Transitioning
75%
Current EPS × Depressed Multiple
Strong
·
Conviction
Undervalued
Trading 83.5% below fair value
You pay
$1.39
Bear
$5.62
Fair
$8.42
Bull
$11.23
Bear
$5.62
+304.1%
EPS continues to decline, 5x multiple
Fair
$8.42
+505.8%
Current EPS stabilizes, 8x multiple
Bull
$11.23
+708.1%
Credible recovery, multiple re-rates to 10x
Key Value Driver
Whether the core business model is intact or structurally impaired
Implied Market Multiple
1.1x
Summary
Our base-case estimate uses Current EPS × Depressed Multiple. We then blend that result with the average analyst price target of $6.02 from 16 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $8.42 per share.
Warnings
Don't assume past cash flow levels will return — the company's troubles may have permanently reduced its ability to generate profits.
A stock can look cheap on paper and still lose half its value if the underlying business is permanently damaged.
The wide range between our best and worst cases is intentional — pretending to know a precise value for a troubled company would be misleading.
Wall Street's average price target is $6.02 (from 16 analysts). Our estimate is 53% above the consensus -- consider that gap carefully.
Key Risks
- Bullish DCF projections are fundamentally unknowable for distressed companies
- M&A speculation can floor the stock above intrinsic value temporarily
- Management credibility is a key input — new CEO expands the bull case